Clinical trials: CMS
Congenital Myasthenic Syndrome
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
Participants will attend up to 4 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with CMS due to mutations in DOK7…
- Trial name
- NCT06078553
- Where
- 33 sites in United States, Austria and 10 more
- Volunteers
- 100 people
- Sponsor
- argenx
Paroxysmal Nocturnal Hemoglobinuria, PNH, Complement-mediated Kidney Disease
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
This study is a first-in-human (FIH) trial of CMS-D017 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose (SAD) study (referred to as Part 1 SAD), and Part 2-a multiple…
- Trial name
- NCT07462780
- Testing
- CMS-D017 Capsule
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Healthy Volunteer
A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)
This single center, open-label, randomized study will investigate the drug-drug interaction potential between multiple doses of RO7033877 and multiple doses of colistin methanesulfonate sodium (CMS).
- Trial name
- NCT02156323
- Testing
- CMS, RO7033877, RO7033877 + CMS
- Where
- Netherlands
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Infections, Pseudomonas
Phase I Study of Colistin Methanesulfonate Sodium
This is a clinical study protocol for a single centre, randomized, double blind, placebo controlled, single and repeat dose study to investigate the safety, tolerability and pharmacokinetics of intravenous dosing of Colistin…
- Trial name
- NCT01449838
- Testing
- Colistimethate sodium, Saline
- Where
- Australia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Congenital Myasthenic Syndrome, CMS
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenital Myasthenic Syndromes.
- Trial name
- NCT06436742
- Testing
- ARGX-119
- Where
- 9 sites in United States, Canada and 4 more
- Volunteers
- 15 people
- Sponsor
- argenx
Uterine Fibroids With Menorrhagia
Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia
Objective This study evaluates whether CMS-D002 capsules are effective in treating menorrhagia in participants with uterine fibroids associated with menorrhagia.
- Trial name
- NCT07402369
- Testing
- CMS-D002 Capsules 10 mg, CMS-D002 Capsules 25 mg, CMS-D002 Capsules 50 mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Myasthenic Syndromes, Congenital
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain…
- Trial name
- NCT02562066
- Testing
- amifampridine phosphate
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Non Cystic Fibrosis Bronchiectasis
Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)
The objective of the trial was to investigate the effect of the use of inhaled CMS, administered b.i.d. via a specific nebuliser for 12 months, compared to placebo in subjects with NCFB chronically infected with P.
- Trial name
- PROMIS-I (NCT03093974)
- Testing
- CMS
- Where
- 85 sites in Australia, Belgium and 10 more
- Volunteers
- 377 people
- Sponsor
- Zambon SpA
Cardiovascular Diseases, Congestive Heart Failure
Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
Heart failure is the primary cause of morbidity and mortality worldwide. Currently drug treatments for heart failure manage the symptoms, but not restore the loss cardiomyocytes due to the very limited regenerative capability in…
- Conditions
- Cardiovascular Diseases, Congestive Heart Failure, Dilated Cardiomyopathy
- Trial name
- NCT04982081
- Testing
- hiPSC-CM therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Heart Failure
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting…
- Trial name
- HEAL-AHF (NCT06340048)
- Testing
- HiCM-188 therapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Healthy Volunteers
Study on the Mass Balance of [14C] CMS-D002 in Healthy Adult Participants in China
This phase 1, single-group study will evaluate the mass balance of [14C] CMS-D002 after a single oral dose in healthy adult participants in China.
- Trial name
- NCT07788482
- Testing
- [14C] CMS-D002
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Evaluate the Safety and Tolerability, Healthy and Overweight or Obese Participants
Phase 1 Study of Ascending Doses of CMS-D008 in Healthy and Overweight/Obese Adults
This study is a first-in-human clinical trial of CMS-D008 conducted in Chinese healthy and overweight or obese adult participants, consisting of three parts: Part-1 Single Ascending Dose (SAD) study (hereinafter referred to as…
- Trial name
- NCT07518589
- Testing
- CMS-D008
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Ischemic Heart Failure, CABG-patients
hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease
This is an exploratory study. A total of 16 patients meeting the inclusion and exclusion criteria and awaiting coronary artery bypass grafting (CABG) surgery will be enrolled.
- Trial name
- NCT07471698
- Testing
- HiCM-188 Chitosan Patch, Blank Chitosan Patch
- Where
- China
- Volunteers
- 16 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Healthcare Fraud Schemes, Kickback Networks
Healthcare Integrity & Anti-Fraud Enforcement
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities.
- Conditions
- Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities, Governance Failures
- Trial name
- PHX-AFK-US (NCT07217730)
- Testing
- Validator-Governed Reform & Regulatory Escalation Protocol, Coalition-Grade Validator Dashboard Module (CVDM-1), Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Truway Health, Inc.
Heart Failure, Heart Failure At NYHA Stage III or IV
IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure
This clinical trial investigates the safety, feasibility, and therapeutic potential of a combined approach using HiCM-188 cardiomyocyte injection delivered intramyocardially alongside either LVAD implantation or CABG surgery in…
- Trial name
- NCT06866600
- Testing
- low dose CABG+iPSC-CMs, High dose CABG/LVAD+iPSC-CMs, CABG/LVAD+Saline
- Where
- China
- Volunteers
- 40 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Heart Failure
Treating Heart Failure With hPSC-CMs
Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes.
- Trial name
- HEAL-CHF (NCT03763136)
- Testing
- hPSC-CM Therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Congenital Myasthenic Syndrome, CMS
A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS)
The purpose of this study is to assess efficacy and safety of adimanebart in participants at least 12 years of age with DOK7-, MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS).
- Trial name
- CoMetS (NCT07746089)
- Testing
- Adimanebart IV
- Volunteers
- 105 people
- Sponsor
- argenx
Osteoarthritis, Degenerative Arthritis
Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting
The primary objective of the study is to determine how the short-term outcome of subjects implanted with the JOURNEY™ II BCS Total Knee System compares to subjects implanted with other PS total knee systems, and to determine if…
- Conditions
- Osteoarthritis, Degenerative Arthritis, Traumatic Arthritis
- Trial name
- NCT02820766
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Smith & Nephew, Inc.
Moderate to Severe Plaque Psoriasis
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of…
- Trial name
- NCT07432854
- Testing
- CMS-D001 50mg, CMS-D001 100mg
- Where
- 21 sites in China
- Volunteers
- 540 people
- Sponsor
- Dermavon Holdings Limited
Superficial Skin and Soft Tissue Infections Caused by Gram-positive Bacteria
A Phase I Clinical Trial to Evaluate CMS-F021 Following Single and Multiple Doses in Healthy Participants
"This study is a first-in-human (FIH) trial of CMS-F021 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose (SAD) study (referred to as Part 1 SAD), and Part 2-a multiple…
- Trial name
- NCT07790770
- Testing
- CMS-F021 Gel, Drug: CMS-F021 Gel healthy participant
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Dermavon Holdings Limited